☆ 4.6 Review

A Perspective on Newly Emerging Proteolysis-Targeting Strategies in Antimicrobial Drug Discovery

ANTIBIOTICS-BASEL (2022)

Related references

Note: Only part of the references are listed.

Editorial Material Chemistry, Medicinal

Proteolysis targeting chimeras in antiviral research

Jenny Desantis et al.

FUTURE MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Host E3 ligase HUWE1 attenuates the proapoptotic activity of the MERS-CoV accessory protein ORF3 by promoting its ubiquitin-dependent degradation

Yuzheng Zhou et al.

Summary: This study reveals the ability of the ORF3 accessory protein of MERS-CoV to induce apoptosis in cells, and identifies the host antiviral protein HUWE1 that can induce ORF3 degradation through the ubiquitin-proteasome system. It enriches our knowledge of the pathogenesis of MERS-CoV and provides new targets and strategies for clinical development of drugs for MERS-CoV treatment.

JOURNAL OF BIOLOGICAL CHEMISTRY (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

PROTAC targeted protein degraders: the past is prologue

Miklos Bekes et al.

Summary: Targeted protein degradation (TPD) is a new therapeutic modality that can tackle disease-causing proteins which are difficult to target with conventional small molecules. PROTAC molecules, utilizing the ubiquitin-proteasome system to degrade target proteins, has achieved clinical proof-of-concept and attracted significant industry activity. Future directions include identifying target classes suitable for TPD, expanding the use of ubiquitin ligases for precision medicine, and extending the modality beyond oncology.

NATURE REVIEWS DRUG DISCOVERY (2022)

Add to Collection

Review Cell Biology

Targeted protein degraders march towards the clinic for neurodegenerative diseases

Md. Imtaiyaz Hassan et al.

Summary: Protein degraders offer several advantages over traditional inhibitors for treating neurological and complex diseases. However, there is a knowledge and resource gap in translating chemical degraders into clinical therapy for neurodegenerative disorders. This article examines the current state of targeted protein degradation and identifies clinical candidates for neurodegenerative diseases, highlighting the challenges and potential future directions for degradation therapeutics.

AGEING RESEARCH REVIEWS (2022)

Add to Collection

Article Chemistry, Medicinal

Discovery of Pentacyclic Triterpenoid PROTACs as a Class of Effective Hemagglutinin Protein Degraders

Haiwei Li et al.

Summary: In this study, a new class of pentacyclic triterpenoid-based PROTACs was designed and synthesized to enhance the degradation of hemagglutinin target. Among these PROTACs, V3 showed the best degradation effect on hemagglutinin, with broad-spectrum anti-influenza A virus activity and did not affect the entry of the virus.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Multidisciplinary Sciences

An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA

Jianyuan Zhao et al.

Summary: Researchers have discovered a compound called APL-16-5 that exhibits antiviral effects against influenza A virus (IAV). APL-16-5 binds to TRIM25 and viral PA protein, leading to the degradation of PA through ubiquitination and proteasome-mediated pathways. This compound shows potent in vivo anti-IAV activity and has the potential to become a new therapeutic option for IAV.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

BacPROTACs mediate targeted protein degradation in bacteria

Francesca E. Morreale et al.

Summary: This study successfully reprogrammed the bacterial protein degradation machinery using small-molecule degraders called BacPROTACs. BacPROTACs not only targeted the substrate receptor but also activated ClpC to unfold protein substrates. The in vivo activity of BacPROTACs was demonstrated in mycobacteria, making it a promising tool for both antibiotic discovery and inducible bacterial protein degradation.

CELL (2022)

Add to Collection

Article Multidisciplinary Sciences

Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy

Jing Gao et al.

Summary: Researchers have developed a new polymeric PROTAC nanoparticle for targeted delivery and degradation of proteins in tumors, combined with photodynamic therapy. This study demonstrates the potential of POLY-PROTACs for precise protein degradation and PROTAC-based cancer therapy.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6

Zhuoxian Cao et al.

Summary: HDAC6 is a potential therapeutic target for treating various diseases, and a degrader targeting HDAC6 can efficiently reduce its levels in cells and attenuate NLRP3 inflammasome activation.

ACS CHEMICAL BIOLOGY (2021)

Add to Collection

Article Chemistry, Medicinal

Indomethacin-based PROTACs as pan-coronavirus antiviral agents

Jenny Desantis et al.

Summary: Indomethacin (INM) has shown antiviral activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in drug repurposing studies. Recent research indicates that the antiviral activity of INM could be attributed to its inhibition of human prostaglandin E synthase type 2 (PGES-2). This study explores the application of Proteolysis Targeting Chimeras (PROTACs) technology to develop more potent INM-derived PROTACs with anti-CoV activity, which showed a strong improvement in antiviral potency compared to INM. Molecular modelling studies suggest that human PGES-2 is a potential target of INM-based antiviral PROTACs, paving the way for the development of host-directed anti-coronavirus strategies.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity

Friedrich Hahn et al.

Summary: The study shows that a PROtac based on a cyclin-dependent kinase inhibitor has strong anti-HCMV activity and potential for broader antiviral applications.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

News Item Biotechnology & Applied Microbiology

Targeted protein degraders crowd into the clinic

Asher Mullard

NATURE REVIEWS DRUG DISCOVERY (2021)

Add to Collection

Review Pharmacology & Pharmacy

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Si-Min Qi et al.

Summary: PROTAC technology is an effective method for degrading target proteins through the ubiquitin-proteasome system, with promising applications in cancer treatment. The first oral PROTACs have shown encouraging results in clinical trials, sparking greater enthusiasm for PROTAC research.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation**

Xiaoxuan Su et al.

Summary: An urgent need for antiviral drugs against COVID-19 has prompted the development of chimeric oligonucleotides designed to degrade specific RNAs of SARS-CoV-2. These chimeras showed twice the degradation efficiency compared to conventional antisense oligonucleotides, and demonstrated potent and broad-spectrum inhibition of SARS-CoV-2 and its mutants in pseudovirus infection models.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Hydrophobic Tagging-Mediated Degradation of Transcription Coactivator SRC-1

So Ra Choi et al.

Summary: An SRC-1 degrader was developed to selectively degrade cellular SRC-1, effectively reducing its levels and suppressing cancer cell migration and invasion by mimicking an unfolded state of SRC-1 through a hydrophobic tagging strategy. This novel approach could have wide applications in developing peptide-based protein degraders with enhanced cellular activity.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Chemistry, Medicinal

Targeted Protein Degradation: The New Frontier of Antimicrobial Discovery?

Matthew Powell et al.

Summary: Targeted protein degradation aims to directly degrade protein targets by hijacking endogenous protein quality control systems, displaying potent nanomolar activity and high target specificity. Rapidly expanding knowledge of the factors driving targeted degradation is paving the way for its application in various diseases, particularly in the field of antibiotic discovery where novel approaches are urgently needed.

ACS INFECTIOUS DISEASES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs

Shanique B. Alabi et al.

Summary: Targeted protein degradation (TPD) is an innovative therapeutic approach that completely removes protein molecules using protein degradation pathways, expanding the druggable space beyond small-molecule inhibitors.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Targeted protein degradation in antibacterial drug discovery?

Pooja Gopal et al.

PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY (2020)

Add to Collection

Review Oncology

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Xin Li et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Editorial Material Chemistry, Medicinal

PROTAC Technology: Opportunities and Challenges

Hongying Gao et al.

ACS MEDICINAL CHEMISTRY LETTERS (2020)

Add to Collection

Review Biochemistry & Molecular Biology

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

Sajid Khan et al.

ONCOGENE (2020)

Add to Collection

Article Chemistry, Multidisciplinary

Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders

Hafeez S. Haniff et al.

ACS CENTRAL SCIENCE (2020)

Add to Collection

Article Biology

Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

Alina Mares et al.

COMMUNICATIONS BIOLOGY (2020)

Add to Collection

Article Chemistry, Medicinal

PROTAC Molecules for the Treatment of Autoimmune Disorders

Robert B. Kargbo

ACS Medicinal Chemistry Letters (2019)

Add to Collection

Review Biochemistry & Molecular Biology

ClpP Protease, a Promising Antimicrobial Target

Carlos Moreno-Cinos et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Structure of McsB, a protein kinase for regulated arginine phosphorylation

Marcin J. Suskiewicz et al.

NATURE CHEMICAL BIOLOGY (2019)

Add to Collection

Article Biology

Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models

M. Catarina Silva et al.

ELIFE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Structural Basis for Recruitment of DAPK1 to the KLHL20 E3 Ligase

Zhuoyao Chen et al.

STRUCTURE (2019)

Add to Collection

Article Multidisciplinary Sciences

Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations

Melissanne de Wispelaere et al.

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Biochemistry & Molecular Biology

The antibiotic cyclomarin blocks arginine-phosphate-induced millisecond dynamics in the N-terminal domain of ClpC1 from Mycobacterium tuberculosis

Katharina Weinhaupl et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2018)

Add to Collection

Article Immunology

Specific MHC-I Peptides Are Induced Using PROTACs

Stephanie M. Jensen et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Arginine phosphorylation marks proteins for degradation by a Clp protease

Debora Broch Trentini et al.

NATURE (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus

Kristopher Montrose et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Inhibitor Mediated Protein Degradation

Marcus J. C. Long et al.

CHEMISTRY & BIOLOGY (2012)

Add to Collection

Article Chemistry, Multidisciplinary

The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease

Esther K. Schmitt et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)

Add to Collection

Article Chemistry, Medicinal

Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics

Ashley R. Schneekloth et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.